RENATA DAMIANI
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
Resumo IPEN-doc 24397 Carbohydrate composition and site-occupancy determination in pituitary and recombinant preparations of human thyrotropin2017 - BARTOLINI, PAOLO; RIBELA, MARIA T.C.P.; DAMIANI, RENATA; SILVA, FELIPE D.; LIMA, ELIANA R.; OLIVEIRA, JOAO E.; PERONI, CIBELE N.; TORJESEN, PETER A.; SOARES, CARLOS R.Human thyrotropin (hTSH) is a glycoprotein with three potential glycosylation sites: two in the -subunit and one in the -subunit. Carbohydrate site-occupancy is frequently neglected in glycoprotein characterization, even if related to folding, trafficking, initiation of inflammation, host defence and congenital disorders of glycosylation (CDG). For the first-time N-glycoprofiling analysis was applied to site-occupancy determination of two native pituitary hTSH, in comparison with three CHO-derived preparations of hTSH, a widely used biopharmaceutical. A single methodology provided: (i) average N-glycan mass; (ii) mass fraction of each monosaccharide and of sulfate; (iii) percent carbohydrate. The results indicate that occupancy (65–87%) and carbohydrate mass (12–19%) can be 34–57% higher in recombinant hormones. The average glycan mass is 24% lower in pituitary hTSH and contains ∼3-fold fewer moles of galactose (P < 0.005) and sialic acid (P < 0.01). The number of moles of fucose per mole of hTSH was found 2.5-fold higher in the pituitary preparations. One of these native preparations, presenting the smallest glycan mass, lowest occupancy, GalNAc, sulfate, Gal and sialic acid contents, also presented the lowest in vivo bioactivity and circulatory half-life. This methodology, extremely important for comparing a recombinant biopharmaceutical to its native equivalent, can be applied to any physiologically or clinical relevant glycoprotein.Artigo IPEN-doc 22995 N-Glycoprofiling analysis for carbohydrate composition and site-occupancy determination in a poly-glycosylated protein: human thyrotropin of different origins2017 - RIBELA, MARIA T.C.P.; DAMIANI, RENATA; SILVA, FELIPE D.; LIMA, ELIANA R.; OLIVEIRA, JOAO E.; PERONI, CIBELE N.; TORJESEN, PETER A.; SOARES, CARLOS R.; BARTOLINI, PAOLOHuman thyrotropin (hTSH) is a glycoprotein with three potential glycosylation sites: two in the -subunit and one in the -subunit. These sites are not always occupied and occupancy is frequently neglected in glycoprotein characterization, even though it is related to folding, trafficking, initiation of inflammation and host defense, as well as congenital disorders of glycosylation (CDG). For the first time N-glycoprofiling analysis was applied to the site-occupancy determination of two native pituitary hTSH, in comparison with three recombinant preparations of hTSH, a widely used biopharmaceutical. A single methodology provided the: (i) average N-glycan mass; (ii) mass fraction of each monosaccharide and of sulfate; and (iii) percent carbohydrate. The results indicate that the occupancy (65%–87%) and carbohydrate mass (12%–19%) can be up to 34%–57% higher in recombinant hormones. The average glycan mass is 24% lower in pituitary hTSH and contains ~3-fold fewer moles of galactose (p < 0.005) and sialic acid (p < 0.01). One of the two native preparations, which had the smallest glycan mass together with the lowest occupancy and GalNAc, sulfate, Gal and sialic acid contents, also presented the lowest in vivo bioactivity and circulatory half-life. The methodology described, comparing a recombinant biopharmaceutical to its native equivalent, can be applied to any physiologically or clinical relevant glycoprotein.Artigo IPEN-doc 20704 N-glycoprofiling analysis in a single glycoprotein model: a comparison between recombinant and pituitary glycosylated human prolactin2015 - CAPONE, MARCOS V.N.; SUZUKI, MIRIAM F.; OLIVEIRA, JOAO E.; DAMIANI, RENATA; SOARES, CARLOS R.J.; BARTOLINI, PAOLOResumo IPEN-doc 16585 First expression of the antagonist of mouse prolactin (S177D-mPRL) by adherent dhfr-CHO cell using p658 vector2011 - SUZUKI, M.F.; ARTHUSO, F.S.; OLIVEIRA, J.E.; CAPONE, M.V.; DAMIANI, R.; OLIVEIRA, N.A.J.; GOULART RODRIGUES, H.; RIBELA, M.T.C.P.; SOARES, C.R.J.; BARTOLINI, P.Resumo IPEN-doc 11009 High-level secretion of growth hormone by retrovirally transduced primary human keratinocytes: prospects for an animal model of cutaneous gene therapy2005 - PERONI, C.N.; CECCHI, C.R.; DAMIANI, R.; SOARES, C.R.J.; RIBELA, M.T.C.P.; ARKATEN, R.R.; BARTOLINI, P.Artigo IPEN-doc 14342 Produção em escala laboratorial de prolactina humana em células CHO adaptadas para o crescimento em suspensão2009 - ARTHUSO, FERNANDA dos S.; SUZUKI, MIRIAM F.; GOULART, HERBERT R.; SOUZA, JOSE M.; OLIVEIRA, JOAO E.; DAMIANI, RENATA; OLIVEIRA, TAIS L.; CAPONE, MARCOS V.N.; BARTOLINI, PAOLO; SOARES, CARLOS R.J.O Grupo de Hormônios do Centro de Biotecnologia do IPEN tem desenvolvido várias linhagens de células de ovário de hamster chinês (CHO) modificadas geneticamente e comprovadamente eficientes na expressão de proteínas heterólogas, dentre elas a prolactina humana (hPRL). No entanto, todas as nossas linhagens são cultivadas aderidas e dependentes da presença de soro fetal bovino (SFB) no meiode cultivo para um crescimento eficiente. Nesse trabalho foi realizada a adaptação da nossa linhagem produtora de hPRL para o crescimento em suspensão e na ausência de SFB. As células em suspensão apresentam um grande interesse industrial-farmacêutico, tanto pela facilidade de cultivo e ampliação de escala, como pela produtividade volumétrica. Os estudos para adaptação dessas células foram realizados com base no protocolo descrito por Sinacore e colaboradores (2000). Desta forma foi realizada uma produção laboratorial de hPRL em frascos "spinner" por 30 dias consecutivos, assim com, a sua purificação e caracterização.Artigo IPEN-doc 16538 Improved bioprocess with CHO-hTSH cells on higher microcarrier concentration provides higher overall biomass and productivity for rhTSH2011 - VENTINI, DANIELLA C.; DAMIANI, RENATA; SOUSA, ALVARO P.B.; OLIVEIRA, JOAO E. de; PERONI, CIBELE N.; RIBELA, MARIA T.C.P.; BARTOLINI, PAOLO; TONSO, ALDO; SOARES, CARLOS R.J.; PEREIRA, CARLOS A.Artigo IPEN-doc 11548 High-level secretion of growth hormone by retrovirally transduced primary human keratinocytes2006 - PERONI, CIBELE N.; CECCHI, CLAUDIA R.; DAMIANI, RENATA; SOARES, CARLOS R.J.; RIBELA, MARIA T.C.P.; ARKATEN, ROSANGELA R.; BARTOLINI, PAOLOA gene therapy clinical trial for treatment of growth hormone (GH) deficiency has not been reached yet, but several strategies using different gene transfer methodologies and animal models have been developed and showed successful results. We have set up an ex vivo gene therapy protocol using primary human keratinocytes transduced with an efficient retroviral vector (LXSN) encoding the human (hGH) or mouse GH (mGH) genes. These stably modified cells presented high in vitro expression levels of hGH (7 μg/106 cells/d) and mGH (11 μg/106 cells/d) after selection with geneticin. When the hGH-secreting keratinocytes were grafted onto immunodeficient dwarf mice (lit/scid), hGH levels in the circulation were about 0.2–0.3 ng/mL during a 12-d assay and these animals presented a significant body weight increase (p<0.01) compared to the control. Substitution of conventional grafting methodologies with organotypic raft cultures revealed a peak value of up to 20 ng mGH/mL in the circulation of grafted lit/scid mice at 1 h postimplantation, followed by a rapid decline to baseline (≈2 ng/mL) within 24 h. One week after grafting, however, the cultured excised implants still presented approx 45% of their original in vitro secretion efficiency. Further studies are being carrier out to identify the main factor(s) that still constitute one of the major impediments to the success of this promising model of cutaneous gene therapy.